Organogenesis yesterday it is releasing results from a comparative effectiveness analysis of its Apligraf and Dermagraf artificial skin grafts showing superior performance compared to its competitors, and released data from a previous study of its graft being used to treat diabetic foot ulcers.
The results will be reported at the Symposium on Advanced Wound Care’s fall meeting this weekend in Las Vegas, Nev.
The grafts were analyzed against MiMedx‘s (NSDQ:MDXG) Epifix, Integra LifeSciences (NSDQ:IART) newly acquired PriMatrix, developed by TEI Biosciences, and Soluble Systems‘ Theraskin, the company said.
“This has been an exciting year for Organogenesis, with the launch of PuraPly and PuraPly antimicrobial, the latest additions to the Organogenesis portfolio of advanced wound care products, and the recent expansion of our sales force. We look forward to showcasing our entire product portfolio at SAWC Fall and sharing new scientific research that demonstrates how our living cell-based products, Apligraf and Dermagraft, work in the hands of hundreds of clinicians in routine clinical settings across the United States,” CEO Gary Gillheeney said in prepared remarks.
Another study, published in the Wound Repair and Regeneration journal, looked at healing rates in patients being treated for diabetic foot ulcers.
The study used Medicare patient record data to analyze real-world medical resource utilization and cost of the grafts compared to conventional care, the company said.
Data from the study of both the Apligraf and Dermagraft showed a 22% and 28% reduction in amputation, 26% and 32% reduction in emergency department visits, 42% and 33% fewer hospital days and savings of $6,991 and $5,253 respectively for the 2 products.
The company’s 2 approved grafts are the only Medicare-reimbursed “skin substitutes”, the company said.
The post Organogenesis touts CE data on artificial skin grafts appeared first on MassDevice.
from MassDevice http://ift.tt/1R62gz7
Cap comentari:
Publica un comentari a l'entrada